Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Bouhnik Y, Pineton de Chambrun G, Lambert J, Nachury M, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Filippi J, Desseaux K, Viennot S, Abitbol V, Boualit M, Bourreille A, Giletta C, Buisson A, Roblin X, Dib N, Malamut G, Amiot A, Fumery M, Louis E, Elgharabawy Y, Peyrin-Biroulet L; MICA-GETAID Study Group. Bouhnik Y, et al. Among authors: pineton de chambrun g. Clin Gastroenterol Hepatol. 2023 Dec;21(13):3365-3378.e5. doi: 10.1016/j.cgh.2023.01.013. Epub 2023 Jan 31. Clin Gastroenterol Hepatol. 2023. PMID: 36731588 Free article.
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L, Bossuyt P, Vuitton L, Irving P, Viennot S, Lamb CA, Pollok R, Baert F, Nachury M, Fumery M, Gilletta C, Almer S, Ben-Horin S, Bouhnik Y, Colombel JF, Hertervig E; GETAID and the SPARE-Biocycle research group. Louis E, et al. Lancet Gastroenterol Hepatol. 2023 Mar;8(3):215-227. doi: 10.1016/S2468-1253(22)00385-5. Epub 2023 Jan 11. Lancet Gastroenterol Hepatol. 2023. PMID: 36640794 Free PMC article. Clinical Trial.
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.
Buisson A, Serrero M, Orsat L, Nancey S, Rivière P, Altwegg R, Peyrin-Biroulet L, Nachury M, Hébuterne X, Gilletta C, Flamant M, Viennot S, Bouguen G, Amiot A, Mathieu S, Vuitton L, Plastaras L, Bourreille A, Caillo L, Goutorbe F, Pineton De Chambrun G, Attar A, Roblin X, Pereira B, Fumery M. Buisson A, et al. Among authors: pineton de chambrun g. Inflamm Bowel Dis. 2023 Apr 3;29(4):579-588. doi: 10.1093/ibd/izac119. Inflamm Bowel Dis. 2023. PMID: 35815744
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.
Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J; I-CARE collaborator group. Amiot A, et al. J Crohns Colitis. 2023 Jan 27;17(1):37-48. doi: 10.1093/ecco-jcc/jjac091. J Crohns Colitis. 2023. PMID: 35767639 Free PMC article.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Nachury M, Amiot A. Fumery M, et al. Among authors: pineton de chambrun g. Aliment Pharmacol Ther. 2021 Oct;54(7):944-951. doi: 10.1111/apt.16544. Epub 2021 Jul 23. Aliment Pharmacol Ther. 2021. PMID: 34296456
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
Wils P, Seksik P, Stefanescu C, Nancey S, Allez M, Pineton de Chambrun G, Altwegg R, Gilletta C, Vuitton L, Viennot S, Serrero M, Fumery M, Savoye G, Collins M, Goutorbe F, Brixi H, Bouguen G, Tavernier N, Boualit M, Amiot A, Abitbol V, Laharie D, Pariente B; PREGNANCY-GETAID study group. Wils P, et al. Among authors: pineton de chambrun g. Aliment Pharmacol Ther. 2021 Feb;53(4):460-470. doi: 10.1111/apt.16192. Epub 2020 Dec 7. Aliment Pharmacol Ther. 2021. PMID: 33345331
Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID.
Buisson A, Filippi J, Amiot A, Cadiot G, Allez M, Marteau P, Bouhnik Y, Pineton de Chambrun G, Pelletier AL, Nancey S, Moussata D, Attar A, Blain A, Vuitton L, Vernier-Massouille G, Seksik P, Nachury M, Dupas JL, Laharie D, Peyrin-Biroulet L, Louis E, Mary JY. Buisson A, et al. Among authors: pineton de chambrun g. J Crohns Colitis. 2021 Jun 22;15(6):1000-1008. doi: 10.1093/ecco-jcc/jjaa250. J Crohns Colitis. 2021. PMID: 33313808
50 results